<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38492007</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-4726</ISSN><JournalIssue CitedMedium="Internet"><Volume>281</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery</Title><ISOAbbreviation>Eur Arch Otorhinolaryngol</ISOAbbreviation></Journal><ArticleTitle>Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics.</ArticleTitle><Pagination><StartPage>3671</StartPage><EndPage>3678</EndPage><MedlinePgn>3671-3678</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00405-024-08548-6</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Although COVID-19 anosmia is often transient, patients with persistent olfactory dysfunction (pOD) can experience refractory parosmia and diminished smell. This study evaluated four putative therapies for parosmia in patients with chronic COVID-19 olfactory impairment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">After screening nasal endoscopy, 85 patients (49 female, 58%) with pOD and treatment-refractory parosmia were randomized to: (1) ultramicronized palmitoylethanolamide and luteolin&#x2009;+&#x2009;olfactory training (OT) (umPEALUT group, n&#x2009;=&#x2009;17), (2) alpha-lipoic acid&#x2009;+&#x2009;OT (ALA group, n&#x2009;=&#x2009;21), (3) umPEALUT&#x2009;+&#x2009;ALA&#x2009;+&#x2009;OT (combination group, n&#x2009;=&#x2009;28), or 4) olfactory training (OT) alone (control group, n&#x2009;=&#x2009;23). Olfactory function was assessed at baseline (T<sub>0</sub>) and 6&#xa0;months (T<sub>1</sub>) using a parosmia questionnaire and Sniffin' Sticks test of odor threshold, detection, and identification (TDI). Analyses included one-way ANOVA for numeric data and Chi-Square analyses for nominal data on parosmia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The umPEALUT group had the largest improvement in TDI scores (21.8&#x2009;&#xb1;&#x2009;9.4 to 29.7&#x2009;&#xb1;&#x2009;7.5) followed by the combination group (19.6&#x2009;&#xb1;&#x2009;6.29 to 27.5&#x2009;&#xb1;&#x2009;2.7), both p&#x2009;&lt;&#x2009;0.01. The control and ALA groups had no significant change. Patients in the combination and umPEALUT groups had significantly improved TDI scores compared to ALA and control groups (p&#x2009;&lt;&#x2009;0.001). Rates of parosmia resolution after 6&#xa0;months were reported at 96% for combination, 65% for control, 53% for umPEALUT and 29% for ALA (p&#x2009;&lt;&#x2009;0.001). All treatment regimens were well-tolerated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">umPEALUT and OT, with or without ALA, was associated with improvement in TDI scores and parosmia, whereas OT alone or OT with ALA were associated with little benefit.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cantone</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Federico II University of Naples, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ascanio</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Ospedali Riuniti Marche Nord, Fano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Luca</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology, Fatebenefratelli Isola Tiberina-Gemelli Isola, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roccamatisi</LastName><ForeName>Dalila</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Psychology Department, UTIU, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La La Mantia</LastName><ForeName>Ignazio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>GF Ingrassia Department, University of Catania, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Di Stadio</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5510-3814</Identifier><AffiliationInfo><Affiliation>GF Ingrassia Department, University of Catania, Catania, Italy. ariannadistadio@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Santa Lucia, Rome, Italy. ariannadistadio@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Otorhinolaryngol</MedlineTA><NlmUniqueID>9002937</NlmUniqueID><ISSNLinking>0937-4477</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73Y7P0K73Y</RegistryNumber><NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004983">Ethanolamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010169">Palmitic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>6R8T1UDM3V</RegistryNumber><NameOfSubstance UI="C005958">palmidrol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="Y">Olfaction Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008063" MajorTopicYN="Y">Thioctic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004983" MajorTopicYN="N">Ethanolamines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010169" MajorTopicYN="N">Palmitic Acids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="N">Anosmia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094562" MajorTopicYN="N">Olfactory Training</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alpha lipoic acid</Keyword><Keyword MajorTopicYN="N">Anosmia</Keyword><Keyword MajorTopicYN="N">Coronavirus long-COVID</Keyword><Keyword MajorTopicYN="N">Palmitoylethanolamide</Keyword><Keyword MajorTopicYN="N">Parosmia</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>16</Day><Hour>21</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>16</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38492007</ArticleId><ArticleId IdType="pmc">PMC11211159</ArticleId><ArticleId IdType="doi">10.1007/s00405-024-08548-6</ArticleId><ArticleId IdType="pii">10.1007/s00405-024-08548-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pellegrino R, Mainland JD, Kelly CE, Parker JK, Hummel T. Prevalence and correlates of parosmia and phantosmia among smell disorders. Chem Senses. 2021;46:bjab046. doi: 10.1093/chemse/bjab046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/chemse/bjab046</ArticleId><ArticleId IdType="pmc">PMC8633731</ArticleId><ArticleId IdType="pubmed">34698820</ArticleId></ArticleIdList></Reference><Reference><Citation>Altundag A. Parosmia and phantosmia: managing quality disorders. Curr Otorhinolaryngol Rep. 2023;11(1):19&#x2013;26. doi: 10.1007/s40136-023-00441-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40136-023-00441-w</ArticleId><ArticleId IdType="pmc">PMC9880375</ArticleId><ArticleId IdType="pubmed">36721659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohla K, Veldhuizen MG, Green T, et al. A follow-up on quantitative and qualitative olfactory dysfunction and other symptoms in patients recovering from COVID-19 smell loss. Rhinol J. 2022;60(3):207&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11016179</ArticleId><ArticleId IdType="pubmed">35398877</ArticleId></ArticleIdList></Reference><Reference><Citation>Altundag A, Yilmaz E, Kesimli MC. Modified olfactory training is an effective treatment method for COVID-19 induced parosmia. Laryngoscope. 2022;132:1433&#x2013;1438. doi: 10.1002/lary.30101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.30101</ArticleId><ArticleId IdType="pmc">PMC9088368</ArticleId><ArticleId IdType="pubmed">35257391</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukahara T, Brann DH, Datta SR. Mechanisms of SARS-CoV-2 associated anosmia. Physiol Rev. 2023;103(4):2759&#x2013;2766. doi: 10.1152/physrev.00012.2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00012.2023</ArticleId><ArticleId IdType="pmc">PMC10625840</ArticleId><ArticleId IdType="pubmed">37342077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralli M, Di Stadio A, Greco A, de Vincentiis M, Polimeni A. Defining the burden of olfactory dysfunction in COVID-19 patients. Eur Rev Med Pharmacol Sci. 2020;24(7):3440&#x2013;3441.</Citation><ArticleIdList><ArticleId IdType="pubmed">32329813</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, D'Ascanio L, La Mantia I, Ralli M, Brenner MJ. Parosmia after COVID-19: olfactory training, neuroinflammation and distortions of smell. Eur Rev Med Pharmacol Sci. 2022;26(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">35049034</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, D'Ascanio L, De Luca P, et al. Hyperosmia after COVID-19: hedonic perception or hypersensitivity? Eur Rev Med Pharmacol Sci. 2022;26(6):2196&#x2013;2200.</Citation><ArticleIdList><ArticleId IdType="pubmed">35363370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreli F, Gaino F, Russo E, et al. Long-term olfactory dysfunction in COVID-19 patients: 18-month follow-up study. Int Forum Allergy Rhinol. 2022;12(8):1078&#x2013;1080. doi: 10.1002/alr.22990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alr.22990</ArticleId><ArticleId IdType="pmc">PMC9082048</ArticleId><ArticleId IdType="pubmed">35199476</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ascanio L, Vitelli F, Cingolani C, et al. Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with palmitoylethanolamide and luteolin": preliminary results. Eur Rev Med Pharmacol Sci. 2021;25(11):4156&#x2013;4162.</Citation><ArticleIdList><ArticleId IdType="pubmed">34156697</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, D'Ascanio L, Vaira LA, et al. Ultramicronized palmitoylethanolamide and luteolin supplement combined with olfactory training to treat post-COVID-19 olfactory impairment: a multi-center double-blinded randomized placebo- controlled clinical trial. Curr Neuropharmacol. 2022;20(10):2001&#x2013;2012. doi: 10.2174/1570159X20666220420113513.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X20666220420113513</ArticleId><ArticleId IdType="pmc">PMC9886808</ArticleId><ArticleId IdType="pubmed">35450527</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P, Camaioni A, Marra P, et al. Effect of ultra-micronized palmitoylethanolamide and luteolin on olfaction and memory in patients with long COVID: results of a longitudinal study. Cells. 2022;11(16):2552. doi: 10.3390/cells11162552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11162552</ArticleId><ArticleId IdType="pmc">PMC9406356</ArticleId><ArticleId IdType="pubmed">36010630</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, Cantone E, De Luca P, et al. Parosmia COVID-19 related treated by a combination of olfactory training and ultramicronized PEA-LUT: a prospective randomized controlled trial. Biomedicines. 2023;11:1109. doi: 10.3390/biomedicines11041109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11041109</ArticleId><ArticleId IdType="pmc">PMC10135838</ArticleId><ArticleId IdType="pubmed">37189728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, Heilmann S, H&#xfc;ttenbriuk KB. Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract. Laryngoscope. 2002;112(11):2076&#x2013;2080. doi: 10.1097/00005537-200211000-00031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005537-200211000-00031</ArticleId><ArticleId IdType="pubmed">12439184</ArticleId></ArticleIdList></Reference><Reference><Citation>Helman SN, Adler J, Jafari A, et al. Treatment strategies for postviral olfactory dysfunction: a systematic review. Allergy Asthma Proc. 2022;43(2):96&#x2013;105. doi: 10.2500/aap.2022.43.210107.</Citation><ArticleIdList><ArticleId IdType="doi">10.2500/aap.2022.43.210107</ArticleId><ArticleId IdType="pmc">PMC8984764</ArticleId><ArticleId IdType="pubmed">35317886</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottle MH, Loring RM. Newer concepts of septum surgery; present status. Eye Ear Nose Throat Mon. 1948;27(9):403&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">18876514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, et al. Normative data for the "Sniffin' Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol. 2007;264(3):237&#x2013;243. doi: 10.1007/s00405-006-0173-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-006-0173-0</ArticleId><ArticleId IdType="pubmed">17021776</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A, Brenner MJ, De Luca P, et al. Olfactory dysfunction, headache, and mental clouding in adults with long-COVID-19: what is the link between cognition and olfaction? A cross-sectional study. Brain Sci. 2022;12(2):154. doi: 10.3390/brainsci12020154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12020154</ArticleId><ArticleId IdType="pmc">PMC8870047</ArticleId><ArticleId IdType="pubmed">35203918</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis BN, et al. Evaluating the clinical usefulness of structured questions in parosmia assessment. Laryngoscope. 2010;120(8):1707&#x2013;1713. doi: 10.1002/lary.20955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.20955</ArticleId><ArticleId IdType="pubmed">20641087</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitcroft KL, Altundag A, Balungwe P, Boscolo-Rizzo P, Douglas R, Enecilla MLB, Fjaeldstad AW, Fornazieri MA, Frasnelli J, Gane S, Gudziol H, Gupta N, Haehner A, Hernandez AK, Holbrook EH, Hopkins C, Hsieh JW, Huart C, Husain S, Kamel R, Kim JK, Kobayashi M, Konstantinidis I, Landis BN, Lechner M, Macchi A, Mazal PP, Miri I, Miwa T, Mori E, Mullol J, Mueller CA, Ottaviano G, Patel ZM, Philpott C, Pinto JM, Ramakrishnan VR, Roth Y, Schlosser RJ, Stj&#xe4;rne P, Van Gerven L, Vodicka J, Welge-Luessen A, Wormald PJ, Hummel T. Position paper on olfactory dysfunction: 2023. Rhinology. 2023 doi: 10.4193/Rhin22.483.</Citation><ArticleIdList><ArticleId IdType="doi">10.4193/Rhin22.483</ArticleId><ArticleId IdType="pubmed">37454287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Ji X. Sample size estimation in clinical research: from randomized controlled trials to observational studies. Chest. 2020;158(1S):S12&#x2013;S20. doi: 10.1016/j.chest.2020.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.03.010</ArticleId><ArticleId IdType="pubmed">32658647</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu DT, Sabha M, Damm M, Philpott C, Oleszkiewicz A, H&#xe4;hner A, Hummel T. Parosmia is associated with relevant olfactory recovery after olfactory training. Laryngoscope. 2021;131(3):618&#x2013;623. doi: 10.1002/lary.29277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.29277</ArticleId><ArticleId IdType="pubmed">33210732</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZY, Vaira LA, Boscolo-Rizzo P, et al. Post-viral olfactory loss and parosmia. BMJ Med. 2023;2:e000382. doi: 10.1136/bmjmed-2022-000382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000382</ArticleId><ArticleId IdType="pmc">PMC10568123</ArticleId><ArticleId IdType="pubmed">37841969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins C, Alanin M, Philpott C, et al. Management of new onset loss of sense of smell during the COVID-19 pandemic&#x2014;BRS consensus guidelines. Clin Otolaryngol. 2021;46(1):16&#x2013;22. doi: 10.1111/coa.13636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/coa.13636</ArticleId><ArticleId IdType="pmc">PMC7461026</ArticleId><ArticleId IdType="pubmed">32854169</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K, Mohanty SK, Mittal A, et al. The cellular basis of loss of smell in 2019-nCoV-infected individuals. Brief Bioinform. 2021;22(2):873&#x2013;881. doi: 10.1093/bib/bbaa168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbaa168</ArticleId><ArticleId IdType="pmc">PMC7462334</ArticleId><ArticleId IdType="pubmed">32810867</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M, Yoo SJ, Clijsters M, et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021;184(24):5932&#x2013;5949.e15. doi: 10.1016/j.cell.2021.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.10.027</ArticleId><ArticleId IdType="pmc">PMC8564600</ArticleId><ArticleId IdType="pubmed">34798069</ArticleId></ArticleIdList></Reference><Reference><Citation>Xydakis MS, Albers MW, Holbrook EH, et al. Post-viral effects of COVID-19 in the olfactory system and their implications. Lancet Neurol. 2021;20(9):753&#x2013;761. doi: 10.1016/S1474-4422(21)00182-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00182-4</ArticleId><ArticleId IdType="pmc">PMC8324113</ArticleId><ArticleId IdType="pubmed">34339626</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwabenland M, Sali&#xe9; H, Tanevski J, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity. 2021;54(7):1594&#x2013;1610.e11. doi: 10.1016/j.immuni.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8188302</ArticleId><ArticleId IdType="pubmed">34174183</ArticleId></ArticleIdList></Reference><Reference><Citation>Altundag A, Y&#x131;ld&#x131;r&#x131;m D, TekcanSanli DE, et al. Olfactory Cleft Measurements and COVID-19-Related Anosmia. Otolaryngol Head Neck Surg. 2021;164(6):1337&#x2013;1344. doi: 10.1177/0194599820965920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599820965920</ArticleId><ArticleId IdType="pmc">PMC7554408</ArticleId><ArticleId IdType="pubmed">33045908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients&#x2014;an MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25:100484. doi: 10.1016/j.eclinm.2020.100484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100484</ArticleId><ArticleId IdType="pmc">PMC7396952</ArticleId><ArticleId IdType="pubmed">32838240</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Aloia A, Molteni L, Gullo F, Bresciani E, Artusa V, Rizzi L, Ceriani M, Meanti R, Lecchi M, Coco S, Costa B, Torsello A. Palmitoylethanolamide modulation of microglia activation: characterization of mechanisms of action and implication for its neuroprotective effects. Int J Mol Sci. 2021;22(6):3054. doi: 10.3390/ijms22063054.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22063054</ArticleId><ArticleId IdType="pmc">PMC8002502</ArticleId><ArticleId IdType="pubmed">33802689</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Abdul Manan H, Heitmann H, et al. The association between depth of the olfactory sulcus, age, gender and olfactory function: an MRI-based investigation in more than 1000 participants. Neuroscience. 2023;519:31&#x2013;37. doi: 10.1016/j.neuroscience.2023.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2023.03.017</ArticleId><ArticleId IdType="pubmed">36934780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonnesu R, Thunuguntla VBSC, Veeramachaneni GK, Bondili JS, La Rocca V, Filipponi C, Spezia PG, Sidoti M, Plicanti E, Quaranta P, Freer G, Pistello M, Mathai ML, Lai M. Palmitoylethanolamide (PEA) inhibits SARS-CoV-2 entry by interacting with S protein and ACE-2 receptor. Viruses. 2022;14(5):1080. doi: 10.3390/v14051080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14051080</ArticleId><ArticleId IdType="pmc">PMC9146540</ArticleId><ArticleId IdType="pubmed">35632821</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwyer DF, Ordovas-Montanes J, Allon SJ, Buchheit KM, Vukovic M, Derakhshan T, Feng C, Lai J, Hughes TK, Nyquist SK, Giannetti MP, Berger B, Bhattacharyya N, Roditi RE, Katz HR, Nawijn MC, Berg M, van den Berge M, Laidlaw TM, Shalek AK, Barrett NA, Boyce JA. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci Immunol. 2021;6(56):eabb7221. doi: 10.1126/sciimmunol.abb7221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abb7221</ArticleId><ArticleId IdType="pmc">PMC8362933</ArticleId><ArticleId IdType="pubmed">33637594</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper SD, Facci L, Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol. 2013;48(2):340&#x2013;352. doi: 10.1007/s12035-013-8487-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8487-6</ArticleId><ArticleId IdType="pubmed">23813098</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Zhang J, Gong M, et al. Research progress of olfactory nerve regeneration mechanism and olfactory training. Ther Clin Risk Manag. 2022;18:185&#x2013;195. doi: 10.2147/TCRM.S354695.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S354695</ArticleId><ArticleId IdType="pmc">PMC8906848</ArticleId><ArticleId IdType="pubmed">35281777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>